Stock FOREST LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Forest Laboratories, Inc.

Equities

US3458381064

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Forest Laboratories, Inc.
2014 Actavis : Factbox - M&A frenzy transforming global pharma RE
2014 Actavis : M&A frenzy in healthcare sector RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Forest Laboratories : Actavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Forest
BU
Forest Laboratories : Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
BU
Forest Laboratories : Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)
BU
Forest Laboratories : Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
BU
Forest Laboratories : to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress
BU
Forest Laboratories : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR®
BU
Forest Laboratories : COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management
BU
Forest Laboratories : Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
BU
Forest Laboratories : Announces Intention to Continue Marketing Both NAMENDA® TABLETS and Once-Daily NAMENDA XR® Into the Fall of 2014
BU
Forest Laboratories : Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
BU
Forest Laboratories : Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
BU
Forest Laboratories : Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
BU
Forest Laboratories : to Present Data about Aclidinium, Aclidinium/Formoterol Combination, and Roflumilast at the American Thoracic Society International Conference
BU
Forest Laboratories : to Present Nebivolol/Valsartan Fixed-Dose Combination Data at the American Society of Hypertension Annual Scientific Meeting
BU
Forest Laboratories : Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest
PR
Forest Laboratories : to Present Data about Levomilnacipran and Vilazodone at the American Psychiatric Association 167th Annual Meeting
BU
Forest Laboratories : Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014
BU
Forest Laboratories : Reports Fiscal Year Fourth Quarter 2014
BU
Forest Laboratories : FURIEX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Furiex Pharmaceuticals
PR
Forest Laboratories : Joins ConvergeHEALTH by Deloitte's Rapid Learning Network in Collaboration with Intermountain Healthcare to Support Insights into Optimal Patient Care
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Forest Laboratories, Inc.
  5. Press Releases